VCM
ALXN

Vigilant Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Vigilant Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11,321
Closed -$2.08M – 825
2021
Q2 		$2.08M Sell
11,321
-26,274
-70% -$4.51M 0.17% 55
2021
Q1 		$5.75M Sell
37,595
-54,308
-59% -$8.4M 0.51% 48
2020
Q4 		$14.4M Buy
91,903
+446
+0.5% +$57.3K 1.38% 39
2020
Q3 		$10.5M Buy
91,457
+752
+0.8% +$81.1K 1.15% 41
2020
Q2 		$10.2M Buy
90,705
+1,153
+1% +$122K 1.24% 39
2020
Q1 		$8.04M Sell
89,552
-17,903
-17% -$1.76M 1.17% 41
2019
Q4 		$11.6M Sell
107,455
-10,120
-9% -$1.08M 1.35% 41
2019
Q3 		$11.5M Buy
117,575
+3,746
+3% +$422K 1.5% 40
2019
Q2 		$14.9M Buy
113,829
+4,467
+4% +$576K 1.99% 23
2019
Q1 		$14.8M Buy
109,362
+2,749
+3% +$342K 2.06% 20
2018
Q4 		$10.4M Sell
106,613
-1,107
-1% -$131K 1.65% 35
2018
Q3 		$15M Buy
107,720
+21,180
+24% +$2.66M 2% 17
2018
Q2 		$10.7M Buy
+86,540
New +$10.1M 1.56% 35
2016
Q3 		– Sell
-150
Closed -$18K – 385
2016
Q2 		$18K Buy
+150
New +$21.3K ﹤0.01% 243

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Vigilant Capital Management's ALXN Position: Q3 2021 in Review

Vigilant Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 11,321 shares — an estimated $2.08M sold.

Vigilant Capital Management first reported a position in ALXN in Q2 2016 and held it in 14 quarters. The position peaked at $15M in Q3 2018. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Vigilant Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Vigilant Capital Management sold 11,321 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2.08M.
  • Vigilant Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2016 and held it in 14 quarters.
  • Vigilant Capital Management's Alexion Pharmaceuticals position peaked at $15M in Q3 2018.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Vigilant Capital Management's 13F filing for Q3 2021, filed 8 Oct 2021.